Clinical Trial Detail

NCT ID NCT03868423
Title Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Sameek Roychowdhury
Indications

Advanced Solid Tumor

Therapies

Brigatinib

Age Groups: adult senior

Additional content available in CKB BOOST